AGP Picks
View all

Octaplas market seen growing on safety, standardization demand

Nov. 9, 2026
Octaplas market seen growing on safety, standardization demand
By AI, Created 17:00 UTC, Nov 09, 2026, AGP -

The Octaplas market is projected to expand as hospitals seek safer, standardized plasma products for trauma, surgery and critical care. A new Business Research Company report points to rising blood disorders, personalized medicine and stronger healthcare infrastructure as major growth drivers.

Why it matters: - Octaplas is used when patients need large-volume plasma transfusions, making demand closely tied to trauma care, surgery and critical care capacity. - The market’s growth reflects a broader shift toward safer, standardized and pathogen-reduced blood products. - Rising blood disorder cases and more personalized treatment approaches are expected to support longer-term demand.

What happened: - The Business Research Company released its Octaplas Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Nov. 9, 2026. - The report says the Octaplas market is set for notable growth as healthcare systems expand and transfusion safety becomes a bigger priority. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period.

The details: - Octaplas is a liquid, pathogen-reduced and standardized plasma product made from pooled human plasma. - The product contains clotting factors and proteins used in plasma replacement. - Octaplas is used in surgical procedures, trauma care and severe coagulopathy. - Historic market growth has come from expanded surgical and trauma services, higher demand for large-volume plasma transfusions, pooled plasma technology and greater use of standardized blood products. - The report expects future growth from increased focus on transfusion safety, more emergency and critical care infrastructure, broader use in complex surgeries, improvements in plasma pathogen inactivation and more investment in blood product standardization. - Key market trends include wider adoption of pathogen-reduced plasma products, more use in trauma and critical care, growth in standardized plasma transfusions, better coagulation management safety and stronger demand for ready-to-use plasma. - Rising blood disorders are a major growth driver. - The report links that trend to environmental pollution, genetic predisposition, lifestyle changes and better diagnostic methods. - In Australia, about 19,403 people were diagnosed with blood cancers in 2022, or roughly 53 new cases a day, according to Leukaemia Foundation data cited in the report. - About 135,000 people in Australia currently live with blood cancers, and that number is expected to top 275,000 by 2035. - Personalized medicine is also supporting market growth. - The Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report package also includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based dashboards, market hotspot infographics and updated graphics and tables. - The report offers a free sample and the full market report through links provided by the publisher: Download the sample report and View the full report.

Between the lines: - The report frames Octaplas as part of a broader move toward blood products that are easier to standardize and safer to use across high-acuity settings. - The emphasis on pathogen reduction and ready-to-use plasma suggests buyers are prioritizing speed, consistency and risk reduction in transfusion care. - North America’s lead likely reflects mature healthcare infrastructure, while Asia-Pacific’s projected growth points to expanding access and medical investment.

What's next: - The market outlook points to continued demand as hospitals expand emergency, surgical and critical care capabilities. - Adoption should continue rising if transfusion safety and product standardization remain top clinical priorities. - Personalized medicine and better blood disorder management are likely to remain important demand drivers through the forecast period. - The report’s broader regional and strategic tools are aimed at helping buyers and investors identify the highest-opportunity markets.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Books & Publishers: Africa

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Books & Publishers: Africa

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.